{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:40:36Z","timestamp":1792168836486,"version":"4.4.0"},"reference-count":83,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Autoinflammatory diseases (AID) are rare diseases presenting with episodes of sterile inflammation. These involve multiple organs and can cause both acute organ damage and serious long-term effects, like amyloidosis. Disease-specific anti-inflammatory therapeutic strategies are established for some AID. However, their clinical course frequently includes relapsing, uncontrolled conditions. Therefore, new therapeutic approaches are needed. Janus Kinase inhibitors (JAKi) block key cytokines of AID pathogenesis and can be a potential option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic review of the literature in accordance with the PRISMA guidelines was conducted. Three databases (MEDLINE, Embase and Cochrane Central Register of Controlled Trials) were searched for publications regarding the use of JAKi for AID. Data from the included publications was extracted and a narrative synthesis was performed. Criteria for defining treatment response were defined and applied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We report data from 38 publications with a total of 101 patients describing the effects of JAKi in AID. Data on Type I Interferonopathies, Adult-Onset Still's Disease (AOSD), Systemic Juvenile Idiopathic Arthritis (sJIA), Familial Mediterranean Fever (FMF), and Beh\u00e7et's Syndrome (BS) was identified. From a total of 52 patients with type I interferonopathies, in seven patients (7\/52, 13.5%) a complete response was achieved, most (35\/52, 67.3%) showed a partial response and a minority (10\/52, 19.2%) showed no treatment response. For AOSD, a complete or a partial response was achieved by eleven (11\/26, 42.3%) patients each. Two sJIA patients achieved complete response (2\/4, 50%) and in two cases (2\/4, 50%) a partial response was reported. Half of FMF patients showed a complete response and the other half had a partial one (3\/6, 50.0%). Amongst BS patients most achieved a partial response (8\/13, 61.5%). Five patients showed no response to therapy (5\/13, 38.5%). Overall, the most frequent AEs were upper respiratory tract infections (17), pneumonia (10), BK virus viremia (10) and viruria (4), herpes zoster infection (5), viral gastroenteritis (2) and other infections (4).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The results from this systematic review show that JAKi can be beneficial in certain AID. The risk of AEs, especially viral infections, should be considered. To accurately assess the risk benefit ratio of JAKi for AID, clinical trials should be conducted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2022.930071","type":"journal-article","created":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:53:13Z","timestamp":1656291193000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Effectiveness and Safety of JAK Inhibitors in Autoinflammatory Diseases: A Systematic Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Zhivana","family":"Boyadzhieva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"Ruffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Pankow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41586-019-1828-5","article-title":"Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease","volume":"577","author":"Lalaoui","year":"2020","journal-title":"Nature."},{"key":"B2","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"n Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1097-2765(02)00599-3","article-title":"The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta","volume":"10","author":"Martinon","year":"2002","journal-title":"Mol Cell."},{"key":"B4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3389\/fimmu.2017.00399","article-title":"NF-kappaB pathway in autoinflammatory diseases: dysregulation of protein modifications by ubiquitin defines a new category of autoinflammatory diseases","volume":"8","author":"Aksentijevich","year":"2017","journal-title":"Front Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"21","author":"Crow","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.autrev.2014.01.058","article-title":"Adult-onset Still's disease","volume":"13","author":"Gerfaud-Valentin","year":"2014","journal-title":"Autoimmun Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.clim.2016.05.010","article-title":"Cytokine profile in adult-onset Still's disease: comparison with systemic juvenile idiopathic arthritis","volume":"169","author":"Inoue","year":"2016","journal-title":"Clin Immunol."},{"key":"B8","first-page":"1544","article-title":"Overproduction of monocyte derived tumor necrosis factor alpha, interleukin (IL) 6, IL-8 and increased neutrophil superoxide generation in Behcet's disease. a comparative study with familial mediterranean fever and healthy subjects","volume":"20","author":"Mege","year":"1993","journal-title":"J Rheumatol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1080\/08820139.2017.1288240","article-title":"Natural Killer Cell Subsets and Their Functional Activity in Behcet's Disease","volume":"46","author":"Cosan","year":"2017","journal-title":"Immunol Invest."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s10067-017-3715-5","article-title":"Familial Mediterranean fever, review of the literature","volume":"36","author":"Alghamdi","year":"2017","journal-title":"Clin Rheumatol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e3449","DOI":"10.1097\/MD.0000000000003449","article-title":"Multiple serum cytokine profiling to identify combinational diagnostic biomarkers in attacks of familial mediterranean fever","volume":"95","author":"Koga","year":"2016","journal-title":"Medicine (Baltimore)."},{"key":"B12","unstructured":"Burden of illness in hereditary periodic fevers: a multinational observational patient diary study2634\n            Kuemmerle-DeschnerJB\n            QuartierP\n            Kone-PautI\n            HentgenV\n            MarzanKA\n            DedeogluF\n          33025894Clin Exp Rheumatol.1272020"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1002\/art.37827","article-title":"AA amyloidosis complicating the hereditary periodic fever syndromes","volume":"65","author":"Lane","year":"2013","journal-title":"Arthritis Rheum."},{"key":"B14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.semarthrit.2019.08.005","article-title":"AA amyloidosis secondary to adult onset Still's disease: About 19 cases","volume":"50","author":"Delplanque","year":"2020","journal-title":"Semin Arthritis Rheum."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(04)17401-1","article-title":"Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist","volume":"364","author":"Hoffman","year":"2004","journal-title":"Lancet."},{"key":"B16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.55563\/clinexprheumatol\/fsq5vq","article-title":"The treatment of adult-onset Still's disease with anakinra, a recombinant human IL-1 receptor antagonist: a systematic review of literature","volume":"39","author":"Giacomelli","year":"2021","journal-title":"Clin Exp Rheumatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3899\/jrheum.130924","article-title":"Discrepancy between clinical and radiological responses to tocilizumab treatment in patients with systemic-onset juvenile idiopathic arthritis","volume":"41","author":"Aoki","year":"2014","journal-title":"J Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/S0952-7915(00)00228-4","article-title":"Signaling by type I and II cytokine receptors: ten years after","volume":"13","author":"Gadina","year":"2001","journal-title":"Curr Opin Immunol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/S0140-6736(21)01255-1","article-title":"Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial","volume":"398","author":"Ruperto","year":"2021","journal-title":"Lancet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/S0140-6736(19)32534-6","article-title":"Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2\/3 trial","volume":"394","author":"van der Heijde","year":"2019","journal-title":"Lancet."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219601","article-title":"Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study","author":"Deodhar","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1172\/JCI98814","article-title":"JAK1\/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies","volume":"128","author":"Sanchez","year":"2018","journal-title":"J Clin Invest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ."},{"key":"B26","volume-title":"Effectiveness and Safety of Janus Kinase Inhibitors for Autoinflammatory Disease: Protocol for a Systematic Review of Case Reports","author":"Zhivana Boyadzhieva","year":""},{"key":"B27","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1472-6947-7-16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","journal-title":"BMC Med Inform Decis Mak."},{"key":"B28","doi-asserted-by":"publisher","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ."},{"key":"B29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12969-019-0322-9","article-title":"Disease course and treatment effects of a JAK inhibitor in a patient with CANDLE syndrome","volume":"17","author":"Boyadzhiev","year":"2019","journal-title":"Pediatr Rheumatol Online J."},{"key":"B30","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/pde.14517","article-title":"Successful treatment of chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) syndrome with tofacitinib","volume":"38","author":"Patel","year":"2021","journal-title":"Pediatr Dermatol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1007\/s10875-018-0485-z","article-title":"A case of CANDLE syndrome","volume":"38","author":"Pereira","year":"2018","journal-title":"J Clin Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/ijms21207767","article-title":"Biological and clinical changes in a pediatric series treated with off-label JAK inhibitors","volume":"21","author":"Pin","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1002\/cpt.936","article-title":"Pharmacokinetics, pharmacodynamics, and proposed dosing of the oral JAK1 and JAK2 inhibitor baricitinib in pediatric and young adult CANDLE and SAVI patients","volume":"104","author":"Kim","year":"2018","journal-title":"Clin Pharmacol Ther."},{"key":"B34","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1053\/j.ajkd.2019.07.010","article-title":"APOL1-Associated collapsing focal segmental glomerulosclerosis in a patient with stimulator of interferon genes (STING)-associated vasculopathy with onset in infancy (SAVI)","volume":"75","author":"Abid","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.108273","article-title":"Baricitinib experience on STING-associated vasculopathy with onset in infancy: A representative case from Turkey","volume":"212","author":"Balci","year":"2020","journal-title":"Clinic Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"636225","DOI":"10.3389\/fimmu.2021.636225","article-title":"Case report: novel SAVI-causing variants in STING1 expand the clinical disease spectrum and suggest a refined model of STING activation","volume":"12","author":"Lin","year":"2021","journal-title":"Front Immunol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1093\/rheumatology\/kex316","article-title":"Type I interferonopathy in a young adult","volume":"56","author":"Manoussakis","year":"2017","journal-title":"Rheumatology (Oxford)."},{"key":"B38","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s12969-017-0186-9","article-title":"Successful use of tofacitinib in a 6-year-old patient with SAVI syndrome","volume":"15","author":"Rodionovskaya","year":"2017","journal-title":"Pediatric Rheumatol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.3389\/fimmu.2018.01535","article-title":"A mutation outside the dimerization domain causing atypical sting-associated vasculopathy with onset in infancy","volume":"9","author":"Saldanha","year":"2018","journal-title":"Front Immunol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"599564","DOI":"10.3389\/fimmu.2020.599564","article-title":"A novel biallelic STING1 gene variant causing savi in two siblings","volume":"11","author":"Alghamdi","year":"2020","journal-title":"Front Immunol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.jaip.2020.11.007","article-title":"Overview of STING-associated vasculopathy with onset in infancy (SAVI) among 21 patients","volume":"9","author":"Fr\u00e9mond","year":"2021","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/j.jaci.2016.07.015","article-title":"Efficacy of the Janus kinase 1\/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children","volume":"138","author":"Fremond","year":"2016","journal-title":"J Allergy Clin Immunol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.3389\/fimmu.2019.02770","article-title":"Novel TMEM173 mutation and the role of disease modifying alleles","volume":"10","author":"Keskitalo","year":"2019","journal-title":"Front Immunol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1007\/s10875-019-00690-9","article-title":"STING-Associated vasculopathy with onset in infancy in three children with new clinical aspect and unsatisfactory therapeutic responses to tofacitinib","volume":"40","author":"Tang","year":"2020","journal-title":"J Clin Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s10875-019-00645-0","article-title":"Efficacy and adverse events during janus kinase inhibitor treatment of SAVI syndrome","volume":"39","author":"Volpi","year":"2019","journal-title":"J Clin Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"176","DOI":"10.21037\/atm-20-6198","article-title":"STING-associated vasculopathy with onset in infancy: a familial case series report and literature review","volume":"9","author":"Wang","year":"2021","journal-title":"Ann Transl Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/art.40805","article-title":"Efficacy of baricitinib in the treatment of chilblains associated with aicardi-gouti\u00e8res syndrome, a type i interferonopathy","volume":"71","author":"Meesilpavikkai","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s11011-021-00716-5","article-title":"Ruxolitinib in aicardi-Gouti\u00e8res syndrome","volume":"36","author":"Mura","year":"2021","journal-title":"Metab Brain Dis."},{"key":"B49","doi-asserted-by":"publisher","first-page":"985","DOI":"10.3389\/fimmu.2020.00985","article-title":"Interstitial lung disease and psoriasis in a child with aicardi-gouti\u00e8res syndrome","volume":"11","author":"Zheng","year":"2020","journal-title":"Front Immunol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/NEJMc2001362","article-title":"Janus kinase inhibition in the aicardi-gouti\u00e8res syndrome","volume":"383","author":"Vanderver","year":"2020","journal-title":"n Engl J Med."},{"key":"B51","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jaci.2021.03.010","article-title":"Successful treatment of a novel type I interferonopathy due to a de novo PSMB9 gene mutation with a Janus kinase inhibitor","volume":"21","author":"Kataoka","year":"2021","journal-title":"J Allerg Clinic Immunol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"2045894019869837","DOI":"10.1177\/2045894019869837","article-title":"Pulmonary arterial hypertension in interferonophaties: a case report and a review of the literature","volume":"9","author":"Trombetta","year":"2019","journal-title":"Pulm Circ."},{"key":"B53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-019-0313-x","article-title":"Treatment of type 1 interferonopathy with Ciclosporin A and baricitinib in a 5 year old boy with heterozygous psmb-8 mutation. pediatric rheumatology conference: 10th congress of international society of systemic auto inflammatory diseases","volume":"17","author":"Rietschel","year":"2019","journal-title":"ISSAID"},{"key":"B54","first-page":"S19","article-title":"Treatment of systemic and refractoryadultonset still's diseasewith tofacitinib. efficacyof jak\/stat pathway inhibition","volume":"20","author":"Aguilera","year":"2020","journal-title":"J Clinic Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/03009742.2020.1729405","article-title":"Tofacitinib-induced remission in refractory adult-onset Still's disease complicated by macrophage activation syndrome","volume":"49","author":"Honda","year":"2020","journal-title":"Scand J Rheumatol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1093\/rheumatology\/key414","article-title":"Treatment of refractory adult onset Still's disease with combination anakinra and baricitinib therapy","volume":"58","author":"Ladhari","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1136\/annrheumdis-2021-eular.2210","article-title":"Jak inhibitors in refractory adult and childhood onset still's disease","volume":"80","author":"Gillard","year":"2021","journal-title":"Annals of the Rheumatic Diseases"},{"key":"B58","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1136\/annrheumdis-2019-216699","article-title":"Tofacitinib in refractory adult-onset Still's disease: 14 cases from a single centre in China","volume":"79","author":"Hu","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1136\/rmdopen-2020-001246","article-title":"Mixed results with baricitinib in biological-resistant adult-onset Still's disease and undifferentiated systemic autoinflammatory disease","volume":"6","author":"Kacar","year":"2020","journal-title":"RMD Open"},{"key":"B60","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1136\/annrheumdis-2020-216983","article-title":"Effectiveness and safety of ruxolitinib for the treatment of refractory systemic idiopathic juvenile arthritis like associated with interstitial lung disease: a case report","volume":"20","author":"Bader-Meunier","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B61","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1542\/peds.2018-2845","article-title":"Tofacitinib Treatment of Refractory Systemic Juvenile Idiopathic Arthritis","volume":"143","author":"Huang","year":"2019","journal-title":"Pediatrics."},{"key":"B62","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1093\/rheumatology\/key384","article-title":"Tofacitinib for familial Mediterranean fever: a new alternative therapy?","volume":"58","author":"Garcia-Robledo","year":"2019","journal-title":"Rheumatol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00296-019-04490-7","article-title":"Tofacitinib for the treatment for colchicine-resistant familial Mediterranean fever: case-based review","volume":"40","author":"Karadeniz","year":"2020","journal-title":"Rheumatol Int."},{"key":"B64","first-page":"88","article-title":"Tofacitinib suppresses disease activity and febrile attacks in a patient with coexisting rheumatoid arthritis and familial Mediterranean fever","volume":"42","author":"G\u00f6k","year":"2017","journal-title":"Acta Reumatol Port."},{"key":"B65","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1136\/annrheumdis-2020-217307","article-title":"A pilot study of tofacitinib for refractory Beh\u00e7et's syndrome","volume":"79","author":"Liu","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B66","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fimmu.2017.00029","article-title":"Canonical and non-canonical aspects of jak-stat signaling: lessons from interferons for cytokine responses","volume":"8","author":"Majoros","year":"2017","journal-title":"Front Immunol."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-eular.3403","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","author":"Cohen","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B68","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/annrheumdis-2019-216852","article-title":"Infections in baricitinib clinical trials for patients with active rheumatoid arthritis","volume":"79","author":"Winthrop","year":"2020","journal-title":"Ann Rheum Dis."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1093\/rheumatology\/kez087","article-title":"A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis","volume":"58","author":"Bechman","year":"2019","journal-title":"Rheumatology (Oxford)."},{"key":"B70","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s40744-021-00410-z","article-title":"Safety profile of upadacitinib up to 3 years in psoriatic arthritis: an integrated analysis of two pivotal phase 3 trials","volume":"21","author":"Burmester","year":"2021","journal-title":"Rheumatol Therap."},{"key":"B71","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"n Engl J Med."},{"key":"B72","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s13075-015-0880-2","article-title":"Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials","volume":"17","author":"Strand","year":"2015","journal-title":"Arthritis Res Ther."},{"key":"B73","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1002\/art.41580","article-title":"Venous thromboembolism risk with JAK inhibitors: a meta-analysis","volume":"73","author":"Yates","year":"2021","journal-title":"Arthritis Rheumatol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/rmdopen-2020-001395","article-title":"Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme","volume":"6","author":"Cohen","year":"2020","journal-title":"RMD Open"},{"key":"B76","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/art.21083","article-title":"Opportunistic infections in polymyositis and dermatomyositis","volume":"53","author":"Marie","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B77","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1080\/1744666X.2020.1763793","article-title":"Systemic lupus erythematosus and risk of infection","volume":"16","author":"Barber","year":"2020","journal-title":"Expert Rev Clin Immunol."},{"key":"B78","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13643-019-1188-0","article-title":"How should systematic reviewers handle conference abstracts? a view from the trenches","volume":"8","author":"Scherer","year":"2019","journal-title":"Systemat Rev."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1136\/annrheumdis-2013-203666","article-title":"Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes","volume":"73","author":"Piram","year":"2014","journal-title":"Ann Rheum Dis."},{"key":"B80","unstructured":"Leader Roberto Giacomelli"},{"key":"B81","unstructured":""},{"key":"B82","unstructured":""},{"key":"B83","unstructured":""}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.930071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:53:20Z","timestamp":1656291200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.930071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":83,"alternative-id":["10.3389\/fmed.2022.930071"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.930071","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"article-number":"930071"}}